What Is LABD? Direxion Daily S&P Biotech Bear 3X Shares

LABD is the Direxion Daily S&P Biotech Bear 3X Shares, a -3x inverse leveraged ETF launched in May 2015. It seeks 300% of the inverse of the daily performance of the S&P Biotechnology Select Industry index, meaning it is designed to rise about 3% on a day biotech falls 1%, and fall about 3% on a day biotech rises 1%. It is a short-term trading tool, not a long-term investment.

LABD's gross expense ratio is roughly 1.07% per year, with a net ratio near 0.95% after excluding acquired fund fees. That is far higher than a typical broad index ETF. For a leveraged inverse fund the cost is on top of the daily-reset decay, so the longer you hold, the more these drags compound against you.

LABD tracks the inverse of the S&P Biotechnology Select Industry Index, an equal-weighted basket of US biotechnology companies. Rather than owning stocks, the fund uses swaps, futures, and short positions to deliver -3x the index's daily return. Note that it targets that -3x exposure on a one-day basis only, not over longer periods.

No. LABD is explicitly designed for single-day exposure and is not meant to be held long term. Because it resets daily, its returns compound, and in volatile or sideways markets that compounding causes decay that erodes value over time, even if biotech ends roughly flat. Holding LABD for weeks or months can produce large losses that do not match -3x the index's cumulative move. Combined with its high expense ratio, long-term holders almost always bleed value. Treat it as a short-term hedge or trade only.

A -3x inverse ETF uses derivatives like swaps and futures to deliver 300% of the opposite of an index's daily return. If the index drops 1% in a day, the fund aims to gain about 3%; if it rises 1%, the fund aims to lose about 3%. The exposure is reset each day, so returns compound over multiple days. This daily reset is why performance over longer periods drifts from a simple -3x of the cumulative move and why decay accumulates in choppy markets.

LABD is not a traditional investment; it is a tactical trading and hedging tool. It may suit experienced traders who want to profit from or hedge a short-term decline in biotech and who watch positions daily. For long-term investors it is generally a poor fit because daily-reset decay, -3x leverage on an already volatile sector, and a high expense ratio tend to erode value over time. Whether it fits depends entirely on your strategy, risk tolerance, and time horizon. Walnut is informational, not investment advice, and a -3x inverse fund carries substantial risk of rapid, large losses.

LABD and LABU are sibling Direxion funds on the same S&P Biotechnology Select Industry index, but opposite in direction. LABD is the -3x bear fund that gains when biotech falls, while LABU is the +3x bull fund that gains when biotech rises. Both are daily-reset leveraged ETFs meant for short-term trading, and both suffer compounding decay if held longer than a day or two. They are not buy-and-hold positions.

Because LABD resets its -3x exposure every day, its returns compound. In a choppy or sideways market, alternating up and down days each shrink the base the fund compounds from, a mathematical effect called volatility decay. Over time this can grind LABD lower even if the underlying biotech index is roughly unchanged. The high expense ratio adds further drag. This is the core reason -3x funds like LABD are intended only for very short holding periods.

Put a few fields side by side: the expense ratio (fees compound over decades), the index or strategy it tracks, the top holdings and how much they overlap with what you already own, the dividend yield, and the AUM, liquidity, and bid-ask spread that affect trading costs. For index funds, tracking error (how closely it follows its index) and tax efficiency matter too. LABD's figures are above; the full method is in Walnut's guide on how to compare ETFs.